You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK):控股子公司就腫瘤免疫藥物VERI-101簽署許可協議

格隆匯5月19日丨復星醫藥(02196.HK)發佈公吿,公司控股子公司Fosun Pharma USA獲VerImmune許可在區域內(即中國大陸及港澳台地區)及領域內(即治療、緩解、診斷或預防人類或動物疾病)使用其專有技術和專利獨家臨牀開發、進口及商業化基於類病毒顆粒的腫瘤免疫藥物VERI-101。

根據披露,許可產品是基於類病毒顆粒的腫瘤免疫藥物,截至該公吿日,其尚處於臨牀前研究階段。許可產品通過引導並活化人體對鉅細胞病毒產生的免疫記憶至腫瘤,以對抗和治療癌症。根據截至目前的研究,許可產品表現出單藥以及與免疫點抑制劑聯合針對多種實體瘤的潛力。截至該公吿日,全球範圍內尚無針對腫瘤免疫的類病毒顆粒產品獲批上市。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account